RHYTHMONE
11.9.2019 07:32:09 CEST | Business Wire | Press release
RhythmOne , LLC, a Tremor International company, today announces it will be bringing the infrastructure, scale and success of its programmatic platform to the Asia-Pacific (APAC) and Latin American (LATAM) markets. The announcement will also be made at the international digital marketing conference DMEXCO, following the company’s successful expansion into Europe earlier this year.
To lead international expansion efforts, today the company also announces the appointment of industry veterans Assaf Suprasky as General Manager of Tremor International’s Israel operations and Gal Topaz as Senior Vice President, Exchange Operations and Business Development. Both executives come to RhythmOne with deep experience in advanced mobile and digital video advertising solutions. Prior to his role at RhythmOne, Suprasky was CEO at personalized advertising specialist myThings, and Topaz was the CEO of programmatic group Feature Forward. Physical business development and sales teams are also now in place and active in Europe, APAC, and LATAM.
The RhythmOne Programmatic Platform is among the world’s largest brand-safe programmatic platforms. Offering technological efficiency at virtually every stage of the process, the global platform helps to effectively connect buyers to sellers and engage consumers on formats spanning video, connected TV (CTV), in-app, and display. A proven leader in the US, the RhythmOne Programmatic Platform reaches 358.8 million uniques globally* and is directly integrated with 600+ premium publishers – resulting in over 10,000 properties. The April 2019 acquisition of RhythmOne by Tremor International (AIM: TRMR) has laid the groundwork for further expansion initiatives and enhancements to the platform, including leveraging the large geographical footprint of the group’s performance division by expanding the RhythmOne Programmatic Platform into Asia.
With brand safety at the heart of its offering – supported by RhythmGuard, RhythmOne’s proprietary brand safety technology – and consistent top-tier ratings in Pixalate’s Seller Trust Indexes for programmatic display, mobile, and video advertising both internationally and in the US, the RhythmOne Programmatic Platform helps deliver high-quality solutions with large scale, and is integrated with the major international players including Google Exchange Bidding and Amazon A9. For publishers, RhythmOne offers a fully-integrated supply monetization platform (SSP) to maximize the value of inventory across desktop, mobile, and connected TV devices. Powered by an enhanced technology stack, the RhythmOne SSP provides web publishers and app developers with full access to a global programmatic ad marketplace.
“We are proud to be hosting a large-scale presence at DMEXCO this year as we take our US success and bring it to the international stage in the Asia-Pacific and Latin American markets,” said Ofer Druker, CEO Tremor International. “Our platform has massive global reach, has unique features and partnerships, and, alongside our market-specific business development professionals, we provide the perfect combination of a world-class product with local support, giving us confidence in delivering our product on an international scale. We are also pleased to welcome Assaf Suprasky and Gal Topaz to the RhythmOne team and are confident that their expertise will help bolster our success by delivering results to both demand clients and supply partners on the global stage.”
*Quantcast Measure, August 2019 / 30 Day Total
-ENDS-
Notes to the editors
RhythmOne is top-rated in the most current Pixalate programmatic seller trust rankings (Q4 2018):
- #1 US and #4 International, Global Seller Trust Index
- #1 Mobile Seller Trust Index
- #1 US and #2 International, Video Seller Trust Index
Since 2018, RhythmOne has been partnered with AU-based Allegiant Media as a reseller for RhythmOne in Australia and New Zealand. RhythmOne will be continuing its partnership with them.
About Tremor International
Tremor International Ltd is a global leader in advertising technologies, operating in more than 70 countries. It has three core divisions: Tremor Video (brand advertising), RhythmOne (media) and Taptica (performance advertising).
RhythmOne drives real business outcomes in multiscreen advertising. Its highly-ranked programmatic platform efficiently and effectively delivers performance, quality, and actionable data to demand and supply-focused clients and partners – and its influencer marketing offering fosters action and awareness by connecting brands with influencers who create and distribute branded content to engaged consumers.
Tremor Video helps advertisers deliver impactful brand stories across all screens through the power of creative video intelligence—innovative video technology combined with advanced audience data and captivating creative. Tremor Video is one of the largest and most innovative video advertising companies in North America, with offerings in CTV, influencer marketing, and private marketplaces.
The Taptica performance business is an end-to-end mobile technology advertising platform that helps the world's top brands reach their most valuable users with the widest range of traffic sources available today. Its proprietary technology leverages big data to target quality media at scale. It works with more than 600 advertisers including Amazon, Alibaba, Bytedance, Netmarble, Stubhub and OpenTable.
Tremor International Ltd is headquartered in Israel and maintains offices throughout the US and Canada, Asia-Pacific, Europe, India, and Latin America, and is traded on the London Stock Exchange (AIM: TRMR).
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," “likely,” "will," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. All statements other than statements of historical fact are statements that could be forward-looking statements, including, but not limited to, statements about the potential and effectiveness of RhythmOne’s programmatic platform. These forward-looking statements are subject to risks and uncertainties, assumptions and other factors that could cause actual results and the timing of events to differ materially from future results that are expressed or implied in the forward-looking statements. Factors that could cause or contribute to such differences include the dynamic and rapidly evolving sector, as well as the highly competitive industry that RhythmOne operates in, which make it difficult to evaluate prospects. These and other risk factors are discussed in RhythmOne’s Annual Report for the period ended March 31, 2018. The forward-looking statements in this article are based on information available to RhythmOne as of the date hereof, and we assume no obligation to update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom